JP2011177182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011177182A5 JP2011177182A5 JP2011083991A JP2011083991A JP2011177182A5 JP 2011177182 A5 JP2011177182 A5 JP 2011177182A5 JP 2011083991 A JP2011083991 A JP 2011083991A JP 2011083991 A JP2011083991 A JP 2011083991A JP 2011177182 A5 JP2011177182 A5 JP 2011177182A5
- Authority
- JP
- Japan
- Prior art keywords
- pla2
- sample
- individual
- activity
- vascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 9
- 208000019553 vascular disease Diseases 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 2
- -1 4-nitrophenylsuccinyl Chemical group 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102100037611 Lysophospholipase Human genes 0.000 claims 1
- 108010058864 Phospholipases A2 Proteins 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54158304P | 2004-02-03 | 2004-02-03 | |
| US60/541,583 | 2004-02-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552204A Division JP5155564B2 (ja) | 2004-02-03 | 2005-02-03 | Ｌｐ−ＰＬＡ２活性を検出する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011177182A JP2011177182A (ja) | 2011-09-15 |
| JP2011177182A5 true JP2011177182A5 (https=) | 2013-03-14 |
Family
ID=34837507
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552204A Expired - Fee Related JP5155564B2 (ja) | 2004-02-03 | 2005-02-03 | Ｌｐ−ＰＬＡ２活性を検出する方法 |
| JP2011083991A Ceased JP2011177182A (ja) | 2004-02-03 | 2011-04-05 | Ｌｐ−ＰＬＡ２活性を検出する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552204A Expired - Fee Related JP5155564B2 (ja) | 2004-02-03 | 2005-02-03 | Ｌｐ−ＰＬＡ２活性を検出する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070281323A1 (https=) |
| EP (2) | EP1718967B1 (https=) |
| JP (2) | JP5155564B2 (https=) |
| DK (1) | DK1718967T3 (https=) |
| ES (1) | ES2416344T3 (https=) |
| WO (1) | WO2005074604A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2341772T3 (es) | 2003-05-28 | 2010-06-28 | Glaxo Group Limited | Ensayo de alto rendimiento para determinar la actividad de lp-pla2. |
| US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| EP1735457A4 (en) * | 2004-04-16 | 2007-08-29 | Glaxo Group Ltd | METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY |
| EP2313778B1 (en) * | 2008-07-18 | 2015-01-28 | Boston Medical Center Corporation | Diagnostics for membranous nephropathy |
| EP2246440A1 (en) * | 2009-04-29 | 2010-11-03 | Aterovax | Enzymatic assay for the quantitative determination of phospholipase a1 or a2 activity in a sample |
| EP2588111A1 (en) * | 2010-07-02 | 2013-05-08 | BG Medicine, Inc. | Statin therapy monitored by galectin- 3 measurement |
| CN102692507B (zh) * | 2011-07-29 | 2015-09-16 | 南京诺尔曼生物技术有限公司 | 脂蛋白相关磷脂酶a2(lppla2)测定试剂盒(胶乳增强免疫比浊法) |
| CN103048457B (zh) * | 2012-11-27 | 2014-12-17 | 同昕生物技术（北京）有限公司 | 心肌梗死预警胶体金试剂盒及其制备方法 |
| US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
| CN104237517B (zh) * | 2013-06-18 | 2016-05-18 | 深圳市安群生物工程有限公司 | 检测人Lp-PLA2蛋白的荧光免疫层析试纸及其制备方法 |
| US20150086999A1 (en) * | 2013-09-24 | 2015-03-26 | Thomas D. Schaal | Long shelf-life kits and methods for standardizing, verifying, calibrating or recalibrating detection of lipoprotein-associated phospholipase a2 |
| CN103792353B (zh) * | 2013-10-17 | 2015-07-15 | 武汉生之源生物科技有限公司 | 一种脂蛋白相关磷脂酶a2含量检测试剂盒及其制备方法 |
| WO2015058158A1 (en) * | 2013-10-18 | 2015-04-23 | Diadexus, Inc. | METHOD FOR DETECTION OF LIPOPROTEIN-SPECIFIC Lp-PLA2 ASSOCIATION |
| US10451624B2 (en) | 2015-02-10 | 2019-10-22 | Shenzhen New Industries Biomedical Engineering Co., Ltd | Reagent kit used for detecting lipoprotein-associated phospholipase A2, and preparation method and application for reagent kit |
| CN104634970B (zh) * | 2015-02-10 | 2017-04-05 | 深圳市新产业生物医学工程股份有限公司 | 用于检测脂蛋白相关磷脂酶a2的试剂盒及其制备和应用 |
| CN104820097A (zh) * | 2015-05-22 | 2015-08-05 | 北京协和洛克生物技术有限责任公司 | 一种定量检测样本中脂蛋白磷脂酶a2浓度的液态芯片试剂盒及其制备方法 |
| US11237167B2 (en) * | 2017-01-24 | 2022-02-01 | Cleveland Heartlab, Inc. | Lp-PLA2 assays and composition with detergent |
| CN109917131B (zh) * | 2019-03-26 | 2021-12-17 | 苏州博源医疗科技有限公司 | 一种脂蛋白磷脂酶a2检测试剂及其制备和使用方法 |
| CN111175242A (zh) * | 2020-03-17 | 2020-05-19 | 湖南新大陆生物技术有限公司 | 一种脂蛋白磷脂酶a2检测试剂盒及其应用 |
| CN111662387A (zh) * | 2020-07-14 | 2020-09-15 | 重庆中元汇吉生物技术有限公司 | 抗人脂蛋白相关磷脂酶a2单克隆抗体及其应用 |
| JP7819983B1 (ja) * | 2025-01-09 | 2026-02-25 | 学校法人松山大学 | 酵素の検出方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4925788A (en) | 1986-10-24 | 1990-05-15 | Immunicon Corporation | Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor |
| US5108933A (en) | 1988-09-16 | 1992-04-28 | Immunicon Corporation | Manipulation of colloids for facilitating magnetic separations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5186827A (en) | 1991-03-25 | 1993-02-16 | Immunicon Corporation | Apparatus for magnetic separation featuring external magnetic means |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| AU670108B2 (en) * | 1992-09-11 | 1996-07-04 | Becton Dickinson & Company | Improved antibodies to plasmodium falciparum |
| DK0590327T3 (da) | 1992-09-11 | 2003-07-28 | Hoffmann La Roche | Påvisning af nukleinsyrer i blod |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| EP0658205B1 (en) | 1993-06-25 | 2000-03-15 | Smithkline Beecham Plc | Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy |
| US5977308A (en) | 1993-10-06 | 1999-11-02 | Icos Corporation | Platelet-activating factor acetylhydrolase |
| EP1096016B1 (en) | 1993-10-06 | 2006-01-11 | Icos Corporation | Platelet-activating factor acetylhydrolase |
| US5656431A (en) | 1993-10-06 | 1997-08-12 | Icos Corporation | Platelet-activating factor acetylhydrolase |
| US5847088A (en) | 1993-10-06 | 1998-12-08 | Icos Corporation | Antibodies specific for platelet-activating factor acetylhydrolase |
| US6630301B1 (en) | 1997-03-14 | 2003-10-07 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum |
| AU2324997A (en) | 1996-03-15 | 1997-10-01 | Penn State Research Foundation, The | Detection of extracellular tumor-associated nucleic acid in blood plasma or ser um using nucleic acid amplification assays |
| US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| CA2320843A1 (en) * | 1998-02-23 | 1999-08-26 | Diadexus, Llc | Methods using pla2 as a marker of metastases and for the diagnosis of selected cancers |
| WO2000024910A1 (en) | 1998-10-28 | 2000-05-04 | Smithkline Beecham Plc | Process of purification of low density lipoprotein associated phospholipase a2 using immobilized metal affinity chromatography |
| JP2002532066A (ja) | 1998-11-16 | 2002-10-02 | ジェンウェイ バイオテック， インコーポレイテッド | 鳥類におけるポリヌクレオチドワクチンを用いる抗体の産生 |
| JP4220603B2 (ja) | 1998-12-02 | 2009-02-04 | アルフレッサファーマ株式会社 | 血小板活性化因子アセチルヒドロラーゼ活性の測定方法 |
| AU2876900A (en) | 1999-02-10 | 2000-08-29 | Cell Works Inc. | Class characterization of circulating cancer cells isolated from body fluids andmethods of use |
| JP2002051164A (ja) * | 2000-05-24 | 2002-02-15 | Victor Co Of Japan Ltd | 音声コンテンツ試聴システム及びシステムサーバ並びに携帯電話機 |
| EP1318154B1 (de) | 2001-12-07 | 2004-06-16 | SIRS-Lab GmbH | Verbindungen zur Bestimmung der Aktivität von Phospholipase A2 |
| ES2341772T3 (es) | 2003-05-28 | 2010-06-28 | Glaxo Group Limited | Ensayo de alto rendimiento para determinar la actividad de lp-pla2. |
-
2005
- 2005-02-03 ES ES05712595T patent/ES2416344T3/es not_active Expired - Lifetime
- 2005-02-03 JP JP2006552204A patent/JP5155564B2/ja not_active Expired - Fee Related
- 2005-02-03 EP EP05712595.7A patent/EP1718967B1/en not_active Expired - Lifetime
- 2005-02-03 DK DK05712595.7T patent/DK1718967T3/da active
- 2005-02-03 EP EP10185947A patent/EP2280282A1/en not_active Withdrawn
- 2005-02-03 US US10/588,339 patent/US20070281323A1/en not_active Abandoned
- 2005-02-03 WO PCT/US2005/003211 patent/WO2005074604A2/en not_active Ceased
-
2011
- 2011-04-05 JP JP2011083991A patent/JP2011177182A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011177182A5 (https=) | ||
| Kuwabara et al. | The pathophysiology of sepsis-associated AKI | |
| TWI774693B (zh) | 偵測分析物之方法、組合物及系統 | |
| Russell et al. | Biosensors for managing the COVID-19 cytokine storm: challenges ahead | |
| Aghamirza Moghim Aliabadi et al. | COVID‐19: A systematic review and update on prevention, diagnosis, and treatment | |
| Breglio et al. | A single nucleotide polymorphism in the Plasmodium falciparum atg18 gene associates with artemisinin resistance and confers enhanced parasite survival under nutrient deprivation | |
| JP2016513094A5 (https=) | ||
| Huang et al. | Serum micro RNA‐29 levels correlate with disease progression in patients with chronic hepatitis B virus infection | |
| JP2016500110A5 (https=) | ||
| Hallstrand et al. | Relationship between levels of secreted phospholipase A2 groups IIA and X in the airways and asthma severity | |
| JP2014012007A5 (https=) | ||
| JP2016536012A5 (https=) | ||
| Van den Bergh et al. | Transcriptome analysis of monocyte-HIV interactions | |
| JP2016118568A5 (https=) | ||
| JP2017505897A5 (https=) | ||
| JP2017503481A5 (https=) | ||
| JP2017500584A5 (https=) | ||
| Yang et al. | Application of omics technology to combat the COVID‐19 pandemic | |
| JP2007508527A5 (https=) | ||
| Rahe-Meyer et al. | An evaluation of cyclooxygenase-1 inhibition before coronary artery surgery: aggregometry versus patient self-reporting | |
| Kumar et al. | From detection to protection: Antibodies and their crucial role in diagnosing and combatting SARS-CoV-2 | |
| Kishimoto et al. | Usefulness of a model-based approach for estimating in vitro P-glycoprotein inhibition potency in a transcellular transport assay | |
| Liang et al. | Modest gains after an 8-week exercise program correlate with reductions in non-traditional markers of cardiovascular risk | |
| Carroll et al. | Post-COVID impairment of memory T cell responses to community-acquired pathogens can be rectified by activating cellular metabolism | |
| Tandarto et al. | miR-155 EXPRESSION UTILIZATION AS A POTENTIAL DIAGNOSTIC BIOMARKER OF HEART FAILURE: A SYSTEMATIC REVIEW: Received 2023-01-03; Accepted 2023-02-09; Published 2023-03-09 |